Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)

This study is testing a combination of two oral targeted drugs — DZD6008 and sunvozertinib — in people with advanced non-small cell lung cancer (NSCLC) whose tumors have specific genetic mutations in a gene called EGFR, and whose cancer has stopped responding to standard EGFR-targeted treatments. **You may be eligible if...** - You are 18 or older with advanced or metastatic non-squamous NSCLC - Your tumor has a confirmed EGFR mutation - You have previously received and progressed on EGFR-targeted therapy (specific requirements vary by study group) - Your cancer is stable in the brain (if brain metastases are present) and you have measurable disease **You may NOT be eligible if...** - You have mixed small-cell and non-small-cell lung cancer - You have certain prior treatment histories (e.g., two or more prior third-generation EGFR inhibitors) - You have active lung inflammation (ILD), active infections (HBV, HCV, HIV), or a history of severe heart rhythm abnormalities - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.